FDA Extends Review of Gene Therapy for Rare Immune Disorder
February 14th 2024Rocket’s application for Kresladi is being extended by three months for regulators to review additional information submitted at the request of the FDA. The new Prescription Drug User Fee Act (PDUFA) date is now June 30, 2024.